These results contribute to the growing body of knowledge on the multifaceted benefits of SGLT-2 inhibitors, underscoring their role not only as effective hypoglycemic agents but also as essential cardiovascular and renal protectors in patients with both HF and T2DM. Here, SLC5A2 is linked to type 2 diabetes mellitus.